Back to top

Image: Bigstock

Novartis AG

Read MoreHide Full Article

Novartis has a strong oncology portfolio of drugs like Afinitor, Exjade, Jakavi, Zykadia, Tasigna, Jadenu and an improved formulation of Exjade. The recent approval of Kisqali in the U.S. and Europe and the FDA panel recommendation for CTL019 also bodes well for the company’s portfolio. Growth drivers like Cosentyx and Entresto, more than offset the impact of generic erosion, mainly due to Glivec. Cosentyx hit blockbuster status in 2016.  Earlier, Novartis announced that it is mulling strategic options for Alcon which includes retaining the business separation via capital market transactions such as a spin-off or an initial public offering. The company will throw more light on its plans for Alcon by the end of 2017. We are also impressed by the progress in biosimilars portfolio as the company is on track to launch four more biosimilars by 2020. Shares of the company have outperformed the industry.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Novartis AG (NVS) - free report >>

Published in